Leadership Appointments, Earnings Conference Calls, Milestone Payments, and Technical Updates - Analyst Notes on Illumina, Alexion, Incyte, Clovis and Keryx

NEW YORK, July 17, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Incyte Corporation (NASDAQ: INCY), Clovis Oncology, Inc. (NASDAQ: CLVS) and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4878-100free.

--
Illumina Inc. Analyst Notes
On July 14, 2014, Illumina Inc. (Illumina) announced the appointment of Tina S. Nova, Ph.D. as the Senior Vice President and General Manager of Illumina's oncology business. She will be responsible in leading the Company's strategy for enabling the oncology community to develop innovative products across the full spectrum of cancer management based on Illumina next-generation sequencing technologies. Jay Flatley, CEO of Illumina commented, "Tina has worked at the forefront of personalized cancer diagnostics and is an excellent addition to Illumina's leadership team given our commitment to working with the oncology community to transform the field." Ms. Nova previously served as the COO of Selective Genetics, a biotechnology company, and also held research and management positions with Ligand Pharmaceuticals and Hybritech. The full analyst notes on Illumina are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/ILMN/report.pdf

--
Alexion Pharmaceuticals, Inc. Analyst Notes
On July 10, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced the Company's plans to release its Q2 2014 financial results on July 24, 2014, Thursday, before the US financial markets open. In conjunction with the earnings release, the Company's management will hold a conference call and audio webcast on the same day at 10:00 a.m. ET. The audio webcast can be accessed via the Investor page of the Company's website. The full analyst notes on Alexion are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/ALXN/report.pdf

--
Incyte Corporation Analyst Notes
On July 8, 2014, Incyte Corp. (Incyte) announced that it has successfully earned a total of $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis. "We are very pleased with the progress that Novartis is making in the global roll-out of Jakavi," stated Hervé Hoppenot, President and CEO of Incyte. "The recent approval of Jakavi in Japan is further evidence of that progress." Incyte plans to record this amount as contract revenue in Q3 2014. Incyte reported that it will also earn an additional $60 million milestone payment post obtaining formal pricing and reimbursement approval for a third major European country, anticipated to occur during H2 2014. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/INCY/report.pdf

--
Clovis Oncology, Inc. Analyst Notes
On July 14, 2014, Clovis Oncology Inc.'s (Clovis) stock increased 2.56% to end the day at $39.67 compared to the previous day's closing price at $38.68. The Company's stock went up 3.58% over the past three trading days, compared to the Nasdaq Composite which rose 0.48% during the same trading period. The full analyst notes on Clovis are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/CLVS/report.pdf

--
Keryx Biopharmaceuticals Inc. Analyst Notes
On July 14, 2014, Keryx Biopharmaceuticals' (Keryx) stock increased 1.79% to end the day at $15.11 compared to the previous day's closing price at $14.84. The Company's stock increased 6.18% over the past one trading month, compared to the Nasdaq Composite which rose 3.01% during the same trading period. The full analyst notes on Keryx are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/KERX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED